Purpose: Assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation to prevent pathological fractures. Better prediction of pathological fracture risk is needed. We evaluated if quantitative measures of FDG avidity can assess femoral pathological fracture risk in patients with metastatic breast cancer (MBC). Patients and Methods: A Health Insurance Portability and Accountability Act-compliant retrospective case-control study was performed under institutional review board waiver. Patients with MBC who received an FDG PET/CT from January 2008 to December 2014 and had pathological fracture of the proximal femur within 3 months of PET/CT were selected as cases. Patients with MBC who had an FDG PET/CT in 2013 were sequentially screened in reverse chronological order to identify patients with proximal femoral metastases on PET/CT but no subsequent pathological fracture to serve as a control group. The prespecified goal was to have twice the number of controls as cases. Target lesions in the proximal femur, from femoral head to 5 cm below the lesser trochanter, were analyzed on FDG PET/ CT for SUV max , SUV mean , metabolic tumor volume, and total lesion glycolysis. Wilcoxon rank sum test was used to compare continuous variables in cases and controls. A nonparametric receiver operating characteristic analysis was performed to assess the ability of quantitative FDG measurements to differentiate between cases and controls. Results: In 27 cases with pathological fracture and 55 controls without pathological fracture, all 4 quantitative measures of FDG avidity were statistically different between cases and controls (P < 0.001). A total lesion glycolysis of 81 could differentiate between fracture and nonfracture patients with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. Conclusions: Quantitative measures of FDG avidity may help identify breast cancer patients at high risk of subsequent pathological fracture of the proximal femur.
B
one is the most common site of distant metastasis from breast cancer, as well as many other malignancies. [1] [2] [3] [4] One of the most debilitating sites of osseous metastasis is the proximal femur, which may result in pain, functional limitations, and pathological fractures. Orthopedic fixation of proximal femoral osseous metastases palliates the disease, substantially improving the patient's quality of life. 4, 5 Prophylactic fixation of proximal femoral lesions, before pathologic fracture, reduces surgical complications, improves quality of life, and even lengthens patient survival. 5, 6 Thus, accurate assessment of pathological fracture risk is critical to optimize the use of prophylactic orthopedic fixation, prevent morbidity, and improve patient outcomes.
The assessment of pathological fracture risk is a difficult and imperfect task. Pathological fracture risk is often estimated using Mirels scoring, 7 which combines the use of radiographs to grade size, location, and radiopacity of metastases, as well as the patient's level of pain, to determine a composite score up to 12. Mirels scores of 9 or above suggested high fracture risk in initial reports 7 ; however, subsequent evaluations found that the specificity of Mirels scoring is only 35% to 50%. [8] [9] [10] Accordingly, better prediction of pathological fracture risk is needed. 18 F-FDG PET/CT allows for evaluation of the level of metabolic activity of osseous metastases, [11] [12] [13] [14] which is known to be important for prognosis of patients with metastatic breast cancer (MBC). 13, 14 The purpose of our study was to determine if quantitative measures of FDG avidity can assess the risk of femoral pathological fractures in patients with MBC.
PATIENTS AND METHODS

Patients
This retrospective single-institution study was performed in compliance with the Health Insurance Portability and Accountability Act and was approved by the institutional review board. The requirement to obtain informed consent was waived by the board.
A Standards for Reporting of Diagnostic Accuracy flow chart of the methods used to select cases and controls is provided in Figure 1 . The Memorial Sloan Kettering Cancer Center Health Information System was searched for patients with MBC, FDG PET/CT from January 2008 to December 2014, and pathological fracture of the proximal femur (femoral head to 5 cm below the lesser trochanter) within 3 months of PET/CT. We used the standard definition of the proximal femur as extending from the femoral head to 5 cm below the lesser trochanter. 15 The presence of pathological fracture was defined as a break in the continuity of bone at the location of an osseous metastasis on x-ray, CT, or MR, or the combination of an incomplete cortical lesion on imaging studies and pain elicited during physical examination during range of motion or manual strength testing against resistance 16, 17 as determined by a fellowship-trained orthopedic oncologist with 32 years of experience (J.H.H.), blinded to the outcome of FDG PET/CTanalyses. These patients were defined as patients with proximal femoral pathological fracture (cases). All cases were examined by the same orthopedic oncologist (J.H.H.). The 6-year screening period was chosen to identify an adequate number of pathologic fracture cases within 3 months of PET/CT. The occurrence of fracture within 3 months of PET/CTwas chosen to limit alterations in disease status at the time of the PET/CT and the time of fracture. The same Health Information System was searched for patients with MBC and FDG PET/CT in 2013, which were sequentially screened in reverse chronological order for a list of comparison patients. The imaging and records of these patients were reviewed for (a) the presence of FDG-avid osseous lesions in the proximal femur; and (b) the absence of pathological fracture over the following 12 months. Patients meeting these criteria were defined as patients without pathologic fracture (controls). We set a prespecified goal of having twice as many controls as cases.
Medical records of both cases and controls were reviewed to document breast cancer histology, histologic grade, estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) phenotype, and history of radiation therapy to the femoral lesion.
FDG PET/CT Scans and Review
PET/CTexaminations were performed according to our institution's clinical protocols on GE Discovery STE, 600, 690, and 710 PET/CT systems, including acquisition of images from the mid skull to upper thigh approximately 60 minutes after IV administration of 12 to 15 mCi of FDG. Patients fasted for more than 6 hours, and finger stick blood glucose levels were less than 200 mg/dL before injection. Spiral CT was obtained for attenuation correction at 60 mA, 120 to 140 kVp, with a 5-mm slice thickness during free breathing. PET was acquired at 3 to 5 minutes per bed position using the 3D mode, typically for 6 to 7 bed positions.
PET/CT scans were reviewed on GE PET VCAR workstations. Reference lesions in the proximal femur (defined as the femoral head to 5 cm below the lesser trochanter) were selected by a dual ABR-and ABNM-boarded radiologist with 8 years of PET/CTexperience (G.A.U.) blinded to the presence or absence of subsequent pathological fracture. A region of interest (ROI) was drawn around each reference lesion using transaxial, coronal, and sagittal images (Fig. 2) . The lesion location was defined as (1) head/neck, if the lesion was entirely above the superior aspect of the greater trochanter; FIGURE 2. Measurement of SUV max , SUV mean , MTV, and TLG in proximal femoral lesions. CT, FDG PET, and fused FDG PET/CT images in transaxial, coronal, and sagittal sections of an FDG-avid proximal femoral osseous metastasis. An ROI was drawn for each reference lesion (green boxes) and checked for correct positioning in all 3 axial planes. SUV max , SUV mean , MTV, and TLG were then obtained using GE PET VCAR software. This is a 76-year-old woman with ER+, PR+, HER2 ductal breast cancer. She went on to have a pathologic fracture of the proximal femur. PET/CT Assessment of Pathologic Fracture Risk (2) trochanteric, if the lesion was entirely beneath the superior aspect of the greater trochanter; or (3) both, if the lesion extended both above and below the superior aspect of the greater trochanter. The lesion location was established based on the FDG PET. SUV max , SUV mean , metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured from the ROI using GE PET VCAR software. SUV max was the single voxel within the ROI with the greatest SUV. Metabolic tumor volume was defined as the cubic centimeter (cm 3 ) volume of voxels with SUV greater than 42% of SUV max , as described in a prior publication. 18 Total lesion glycolysis was defined as the product of MTV and SUV mean of voxels within the MTV. 18 
Statistical Methods
The Wilcoxon rank sum test was used to compare continuous variables (age, SUV, tumor volume, and TLG), and Fisher exact test was used to compare categorical variables between patients with pathological fracture and patients without pathological fracture. A nonparametric receiver operating characteristic (ROC) analysis was performed to assess the ability of using each quantitative measure of FDG avidity (SUV max , SUV mean , MTV, and TLG) to differentiate fractured patients from others. The area under the curve (AUC) was estimated. Exploratory cutoff points were found by maximizing Youden index on the ROC curve for each FDG avidity along with observed sensitivity, specificity, positive predictive value, and negative predictive value. In the multivariable analyses, first among clinical factors, location and radiation were found to be associated with risk of fracture via stepwise selection. Then for each measure of FDG avidity, a multivariable logistic regression was used to examine its association with risk of fracture, controlling for location and radiation. All analyses were performed with software packages SAS 9.2 (SAS Institute, Cary, NC) and R version 3.1 (The R Foundation for Statistical Computing).
RESULTS
Characteristics of Cases and Controls
Twenty-seven patients met criteria for cases with pathological fracture of the proximal femur (Fig. 1) . The median age of these patients was 62 years (range, 35-86 years). All 27 cases had an FDG-avid osseous lesion in the proximal femur that subsequently fractured. Fifty-five patients met criteria for controls without pathological fracture of the proximal femur. The median age of these patients was 58 years (range, 32-82 years). Most patients were ductal in histology (59/82, 72%), with high histologic grade (grade 3 51/ 82, 62%). Eleven (13%) of 82 lesions had been previously radiated, including 7 (20%) of 27 patients with fracture and 4 (7%) of 55 patients without fracture. In these 11 patients, radiation therapy was performed between 8 and 26 months before fracture. The majority of lesions (50/82, 61%) extended from the head/neck of the femur into the trochanteric region. Seventy-four (90%) were lesions from ER-positive/HER2-negative malignancies, whereas 4 (5%) were HER2-positive and 4 (5%) were triple-negative. Characteristics of cases and controls are summarized in Table 1 . 
Differences in Patient Characteristics Between Cases and Controls
A greater risk of pathological fracture was correlated with lesions that had been previously radiated (P = 0.035), those from a triple-negative malignancy (P = 0.01), and those that involved the head/neck of the femur without extension into the trochanteric region (P = 0.006, Table 1 ). No statistically significant differences were noted between the cases and controls for age, histology, or histologic grade.
Differences in Quantitative Measurements of FDG Avidity Between Cases and Controls
All 4 quantitative measures of FDG avidity demonstrated statistically significant differences between cases with subsequent pathologic fracture and controls without subsequent pathologic fracture (Table 1) . SUV max , MTV, and TLG were all significant with P < 0.001, whereas SUV mean was significant with P = 0.001. For all 4 measures of FDG avidity, cases with pathological fracture demonstrated higher values than for controls without pathological fracture. Box plots for median and interquartile range for each of the 4 measures of FDG avidity in cases and controls are visually represented in Figure 3 .
ROC Analysis Based on Measures of FDG Avidity
Cutoff values were determined to maximize the combination of sensitivity and specificity of quantitative measures of FDG avidity to identify patients with subsequent risk of pathological fracture (Table 2) . Optimal cutoffs were SUV max 9.55 g/cm 3 , SUV mean 3.35 g/cm 3 , MTV 18.9 cm 3 , and TLG 81.02 g. The AUC was greatest for the volumetric measures MTV and TLG. A TLG of 81.02 g could differentiate patients who would experience subsequent pathological fracture from those who would not with accuracy, sensitivity, and specificity of 0.83, 0.85, and 0.80, respectively. Receiver operating characteristic curves for the 4 measures of FDG avidity to differentiate patients with pathological fracture are shown in Figure 4 .
Multivariate Analyses
Four multivariate models were derived, 1 for each measure of FDG avidity (SUV max , SUV mean , MTV, and TLG). After controlling for clinical factors that were statistically significant (tumor location and prior radiation), all 4 measures of FDG avidity remained significant for the risk of fracture (Table 3) . For SUV max , an increase in SUV max of 1 (incremental unit = 1) was associated with an increased odds of fracture of 1.32 (95% confidence interval [CI], 1.13-1.55). For MTV, an increase in MTV of 5 cm 3 was associated with an increased odds of fracture of 1.54 (95% CI, 1.25-1.91).
DISCUSSION
Prediction of pathological fractures is important because prophylactic treatment of proximal femoral lesions before a pathological fracture occurs will reduce surgical complications, enhance quality of life, and lengthen patient survival. 5, 6 In this manuscript, The measures of accuracy were estimated assuming patients with values above the cutoff values had fracture. PPV, positive predictive value; NPV, negative predictive value.
we propose that FDG PET/CT may help identify breast cancer patients at high risk of proximal femoral pathological fracture. We use quantitative measures of FDG avidity to identify subsequent fracture risk. For the most commonly used measure of FDG avidity, SUV max , sensitivity and specificity of 58% and 85% were achieved, respectively, better than reported values for Mirels criteria. [8] [9] [10] For the volumetric measurement TLG, which accounts both for size and intensity of FDG avidity, sensitivity and specificity were 85% and 80%, respectively. Quantitative measurements that incorporate lesion size, such as MTV and TLG, account for the possibility that larger lesions may be more likely to fracture. If our results are confirmed, then measures of FDG avidity could be used to help predict risk for pathological fracture and identify patients for referral for prophylactic management of high-risk lesions.
A case-control design was selected for this study to efficiently examine the risk factor, extent of tumor metabolism, for pathological fracture. Limiting measurements to lesions in the proximal femur of breast cancer patients was prespecified. Metastatic breast cancer patients were selected because they commonly experience bone metastases, and the proximal femur was selected because it is the most common site affected by metastases that requires treatment. It is also the focus of the accepted Mirels system to predict fracture risk. Inclusion of multiple sites of fracture or multiple tumor types would have added additional variables, made analysis more difficult, and possibly obscured significant results.
The patient population in this study was similar to the population of patients with breast cancer as a whole, in that the distributions of ductal and lobular histology and histologic grade were representative. 19, 20 Of note, the patient population in this study was more often ER-positive/HER2-negative (74/82; 90%) than the breast cancer population as a whole (70%-80%). 21 The reason for this difference is not clear.
Only FDG-avid osseous lesions of the proximal femur were included in this study. This does not discount the importance of non-FDG-avid osseous metastases, which may be seen in patients with breast cancer, may be more common in certain histologies of breast cancer such as lobular breast cancer, 22, 23 and are sources of skeletal events including pathological fracture. The risk of pathological fracture in non-FDG-avid osseous lesions was not assessed in our analysis.
Radiation therapy to proximal femoral lesions was significantly associated with increased risk of pathological fracture (P = 0.035). This is concordant with prior work suggesting that radiation therapy of osseous lesions, while important for pain control and improvement of function, may increase the risk of pathological fracture. 4 As prior radiation therapy increased risk of pathologic fracture, it was controlled for in multivariate analyses.
Other imaging modalities have also been evaluated for their ability to predict pathological fracture. For example, CT structural rigidity analysis, based on quantitative CT scans of the proximal femur, has recently been reported to have improved association with pathological fracture, but this requires special phantoms, calibration, and analysis. 21 Our study had several limitations. The retrospective, singleinstitution design lends itself to selection biases that are difficult to control. We preselected the ranges of patient inclusion and the goal of 2 controls per case in an effort to minimize these selection biases. In the control group of patients without pathological fracture, proximal femoral lesions were not pathologically confirmed as metastases, although all of the patients had pathologically confirmed metastatic disease and FDG-avid osseous lesions in a patient with known MBC are most consistent with osseous metastases. Our institution uses multiple PET/CT systems, and the use of multiple systems could affect the data.
In conclusion, this retrospective case-control study uses parameters for using quantitative measures of FDG avidity to predict the likelihood of subsequent pathological fracture of the proximal femur in patients with MBC. Measures of FDG avidity may help predict risk for pathological fracture and identify patients for referral for prophylactic management of high-risk lesions. This is a novel application of quantitative FDG PET imaging. Our results need to be substantiated in larger and/or prospective study designs. 
